Assembly Biosciences, Inc.

ASMB Healthcare Biotechnology

Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

20.34 2.43 −10.67%
Market cap
$463.6M
P/E
19.9×
Fwd P/E
−21.1×
Dividend yield
—
F-score
4/9
Altman Z
1.06
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — — 3 3 3 — — — 4
P/E ratio
— 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Altman Z-Score
— 6.31 3.43 2.98 0.91 (3.29) — (8.44) (9.38) 1.06
P/S ratio
— 91.05 34.83 33.64 2.71 1.24 — 0.56 3.32 5.27
Altman Z″-Score (non-manufacturers)
— (0.54) 2.37 3.04 3.24 (2.68) — (16.91) (21.02) (1.34)
P/FCF ratio
— 965.84 0.00 0.00 0.00 0.00 — 2.03 0.00 0.00
Beneish M-Score
— — (2.89) (2.34) (0.55) (3.55) — — — —
P/Operating CF
— (84.05) (30.82) (26.16) (8.48) (5.21) — 0.62 (232.82) 26.78
P/B ratio
— 7.26 2.45 1.97 0.89 0.60 — 1.11 2.84 1.84
Price to Tangible BV
— 11.49 3.05 2.32 1.08 0.79 — 0.00 0.00 2.31
EV/Sales
— 77.75 20.10 16.48 (0.03) (0.56) — (1.04) (0.61) 1.84
EV/EBITDA
— 0.00 0.00 0.00 0.03 0.51 — 1.16 0.35 0.00
EV/Operating CF
— 376.99 (4.58) (3.13) 0.03 0.49 — (3.72) 0.34 (3.24)
EV/FCF
— 824.76 (4.56) (3.07) 0.03 0.48 — (3.76) 0.34 (3.24)
Quick Ratio
7.44 9.06 11.94 11.35 8.91 9.14 5.68 3.32 2.34 5.11
Current Ratio
7.52 9.13 12.05 11.57 9.19 9.59 5.95 3.41 2.42 5.22
Net Debt/EBITDA
1.17 2.31 2.36 2.64 3.38 1.63 0.98 1.98 2.29 17.31
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.07 0.07 0.05 0.25 0.03 0.00 0.06 0.22 0.38
Operating CF/Net income
0.79 (0.04) 0.72 0.86 1.01 0.72 0.91 (0.37) 1.27 6.71
Capex/Depreciation
(1.84) (3.95) (0.82) 1.25 (0.69) (0.05) (0.16) 0.20 0.01 0.03
ROE
(44.57%) (44.36%) (56.06%) (40.36%) (24.19%) (63.42%) (74.00%) (98.95%) (107.92%) (5.10%)
ROA
(38.18%) (32.02%) (41.50%) (32.12%) (19.95%) (54.75%) (63.58%) (51.32%) (31.39%) (3.25%)
ROIC
(105.14%) 0.00% 0.00% 0.00% (167.54%) (371.85%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(94.84%) (38.75%) (44.36%) (37.53%) (30.82%) (93.24%) (114.34%) (64.49%) (59.10%) (2.97%)
Average Days of Receivables
— 92.03 59.91 77.15 5.68 19.61 0.00 2.19 0.00 4.92
Research and Development Expense of Revenue
0.00% 490.35% 491.36% 537.22% 135.04% 1,095.68% 0.00% 682.67% 196.12% 89.64%
Selling, General and Administrative Expense of Revenue
0.00% 188.72% 235.06% 206.22% 46.85% 460.19% 0.00% 319.82% 63.14% 27.12%
Intangible Assets out of Total Assets
0.42 0.25 0.16 0.12 0.15 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 95.37% 192.41% 128.79% 27.63% 83.74% 0.00% 71.46% 10.94% 6.47%
Graham Net Nets
— 0.08 0.32 0.40 0.85 1.31 — 0.83 0.31 0.53
Graham Number
— 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Earnings Yield
— (5.32%) (17.69%) (18.19%) (28.94%) (129.67%) — (133.26%) (42.59%) (2.18%)
Free Cash Flow Yield
— 0.10% (12.67%) (15.94%) (29.60%) (94.87%) — 49.38% (53.97%) (10.79%)
Revenue per Share
0.00 6.10 7.79 7.30 26.81 1.73 0.00 1.57 4.75 6.45
Operating CF per Share
(24.31) 1.26 (34.20) (38.43) (21.33) (25.91) (20.94) 4.97 (8.51) (3.67)
Capex per Share
(0.10) (0.58) (0.18) (0.71) (0.16) (0.62) (0.03) (0.05) 0.00 (0.01)
Free Cash Flow per Share
(24.41) 0.67 (34.38) (39.14) (21.49) (26.53) (20.96) 4.92 (8.52) (3.67)
Cash per Share
36.91 81.12 114.82 125.28 73.33 40.67 22.71 28.46 18.66 22.13
Shareholders Equity per Share
55.67 76.50 110.91 124.90 81.52 46.86 20.49 8.98 5.56 18.44
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
55.67 76.50 110.91 124.90 81.52 46.86 20.49 8.98 5.56 18.44
Free Cash Flow
(35.03) 1.00 (65.30) (85.62) (63.43) (95.63) (84.56) 22.51 (51.14) (41.16)
Working Capital
46.45 109.63 204.03 258.34 200.06 138.13 80.67 94.56 67.70 205.77
Capital Expenditures
(0.15) (0.86) (0.34) (1.55) (0.47) (2.24) (0.10) (0.23) (0.03) (0.07)
Net Current Asset Value
35.33 66.94 165.11 216.09 181.82 132.07 77.84 38.06 29.69 203.71
EV/EBIT
— 0.00 0.00 0.00 0.03 0.35 — 1.31 0.38 0.00
Capex to Sales
0.00 0.10 0.02 0.10 0.01 0.36 0.00 0.03 0.00 0.00
Price to Operating Income
— 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.37 0.25 0.74 (0.68) 0.42 37.48 0.88 (2.95) (12.43) (10.03)
Cash ROIC
(26.37%) 0.43% (15.23%) (15.65%) (13.88%) (30.31%) (48.52%) 13.14% (35.17%) (9.05%)
Accounts Receivable Turnover
— 3.84 6.29 5.50 34.36 7.99 0.00 14.51 0.00 142.19
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 — — — — 0.00 0.00 — — —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
0.00 — — — — 0.00 0.00 — — —
Average Receivables
— 2.35 2.35 2.90 2.30 0.78 0.64 0.49 — 0.51
Average Payables
1.87 2.25 2.91 2.71 3.16 3.63 2.58 1.48 0.52 0.88
Average Assets
115.93 133.71 218.67 303.98 311.58 237.16 146.43 119.31 128.00 188.38
Average Common Equity
99.31 96.50 161.89 241.94 256.90 204.75 125.80 61.88 37.23 120.06

Fold the line items

Columns are period end dates